UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                   FORM 10-QSB
(Mark One)
         X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                 For the quarterly period ended: March 31, 2007

       [] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
                        For the transition period from to
                         Commission file number: 0-12968

                        InMedica Development Corporation
        (Exact name of small business issuer as specified in its charter)

             UTAH                                           87-0397815
(State or other jurisdiction of                (IRS Employer Identification No.)
incorporation or organization)

                         825 North 300 West, Suite N132
                           Salt Lake City, Utah 84103
                    (Address of principal executive offices)

                                 (801) 521-9300
                           (Issuer's telephone number)

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes v No ??

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).Yes ?? No v

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:  18,629,493 shares of $.001 par value
common stock as of May 12, 2007


                                       1
<PAGE>



PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements

                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                           CONSOLIDATED BALANCE SHEET



                              ASSETS
                              ------
                                              As of
                                             March 31,
                                              2007
                                           (Unaudited)
                                           -----------

        CURRENT ASSETS:
           Cash & cash equivalents          $   19,112
           Accounts receivable                     200
           Prepaid expenses and other              200
                                             ----------
                Total current assets            19,512

        EQUIPMENT AND FURNITURE,
          at cost, less accumulated
          depreciation of $254,486                 735
                                             ----------

                 Total assets                $   20,247
                                            ==========
















            See notes to consolidated financial statements


                                       2

<PAGE>



                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                     CONSOLIDATED BALANCE SHEET (Continued)



             LIABILITIES AND STOCKHOLDERS' EQUITY
            -------------------------------------
                                                          As of
                                                         March 31,
                                                           2007
                                                          ------
                                                        (Unaudited)
         CURRENT LIABILITIES:
           Related party consulting fees payable       $    60,000
           Note payable                                    129,284
           Accrued interest                                  5,624
           Related party royalty payable                    43,333
           Preferred stock dividend payable                 43,503
                                                      ------------
                Total current liabilities                  281,744
                                                      ------------

            MINORITY INTEREST                            (117,210)
                                                      ------------

        STOCKHOLDERS' EQUITY:
           Preferred stock, 10,000,000
            shares authorized; Series A
            preferred stock, cumulative and
            convertible, $4.50 par value,
            1,000,000 shares designated,
            21,016 shares issued and
            outstanding                                     94,573
           Common stock, $.001 par value;
            40,000,000 shares authorized,
            18,629,493 issued and outstanding               18,629
           Additional paid-in capital                    8,426,839
           Accumulated deficit                          (8,684,328)
                                                        ----------
                 Total stockholders equity                 (144,287)
                                                        ----------
                Total liabilities and
                 stockholders' equity                   $   20,247
                                                        ==========










            See notes to consolidated financial statements


                                       3
<PAGE>



                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF OPERATIONS

                                               For the Three
                                               Months Ended
                                                 March 31,
                                             2007        2006
                                           --------    --------
                                                (Unaudited)
          TOTAL ROYALTY REVENUES            $   -0-         -0-
                                           --------    --------

          OPERATING EXPENSES:
            General and
              administrative                 52,887      34,654
            Research and
             development                        -0-         -0-
                                           --------    --------
              Total operating expenses       52,887      34,654
                                           --------    --------

          LOSS FROM OPERATIONS              (52,887)    (34,654)
                                           --------    --------

          OTHER (EXPENSE) INCOME
            Other (expense) income, net      (2,714)        107
                                           --------    --------
             Total other (expense) income    (2,714)        107
                                           --------    --------

          LOSS BEFORE MINORITY INTEREST     (55,601)    (34,547)

          MINORITY INTEREST                  23,848       1,762
                                           --------    --------
              NET LOSS                      (31,753)    (32,785)

              PREFERRED STOCK DIVIDENDS      (1,892)     (1,892)
                                           --------    --------

          NET LOSS APPLICABLE TO
           COMMON STOCKHOLDERS             $(33,645) $ (34,677)
                                           ========   =========
          NET LOSS PER COMMON SHARE
            (BASIC AND DILUTED)            $   (.00)  $   (.00)
                                           ========   ========

          Weighted average number
           of common shares outstanding   18,629,493  18,129,493
                                           =========  =========






            See notes to consolidated financial statements.

                                       4
<PAGE>



                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF CASH FLOWS


                                                     For the Three
                                                     Months Ended
                                                      March 31,
                                                    2007       2006
                                                  --------   --------
                                                      (Unaudited)
     CASH FLOWS FROM OPERATING ACTIVITIES:

       Net loss                                  $ (31,753) $( 32,785)
       Adjustments to reconcile net
         loss to net cash used in
         operating activities-
           Depreciation and amortization               123        155
           Interest income from amortization
             or discount on notes receivable           -0-       (335)
           Minority interest in losses             (23,848)    (1,762)
           Change in assets and liabilities
             Account receivable                       (200)       -0-
             Consulting fee payable to
               related party                         6,000      6,000
             Royalty payable to
               Related party                        10,000        -0-
             Accounts payable                          -0-      3,762
             Accrued interest payable                2,713        229
             Accrued payroll and related taxes         -0-     (5,553)
                                                  --------   --------
                Net cash used in
                  operating activities             (36,965)   (30,289)
                                                  --------   --------

     CASH FLOWS FROM INVESTING ACTIVITIES:
       Proceeds from note receivable                   -0-     45,000
                                                 ---------  ---------
                 Net cash provided by
                   investing activities                -0-     45,000
                                                 ---------  ---------

     CASH FLOWS FROM FINANCING ACTIVITIES:
       Proceeds from notes payable                  21,998     13,250
       Payments on notes payable                       -0-     (9,000)
       Proceeds from sale of common stock              -0-        -0-
                                                  --------  ---------
                Net cash provided by
                  financing activities              21,998      4,250
                                                  --------   --------



           See notes to consolidated financial statements.

                                       5
<PAGE>



                INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)

                                                      For the Three
                                                       Months Ended
                                                         March 31,
                                                      2007      2006
                                                   ---------- -------
                                                      (Unaudited)


   NET INCREASE IN CASH                          (14,967)      18,961

   CASH AT BEGINNING OF PERIOD                    34,079       51,885
                                                 -------     --------

   CASH AT END OF PERIOD                        $ 19,112      $70,846
                                                 =======      =======































          See notes to consolidated financial statements.

                                       6
<PAGE>


INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


1.       Basis of Presentation

The  accompanying  unaudited  consolidated  financials  statements  of  InMedica
Development  Corporation  and its  majority  owned  subsidiary,  MicroCor,  Inc.
(collectively  the Company)  have been  prepared on a going  concern basis which
contemplates  the  realization of assets and  satisfaction  of liabilities  that
might be necessary  should the Company be unable to continue as a going concern.
The  Company  generated  a net loss of $31,753  and  $32,785 for the three month
periods  ended March 31, 2007 and 2006,  respectively,  and negative  cash flows
from  operations  of $36,965 and $30,289 for the three month periods ended March
31,  2007 and 2006,  respectively.  As of March 31,  2007,  the  Company  had an
accumulated  deficit  of  $8,684,328.  At March  31,  2007,  the  Company  had a
stockholder's  deficit of $144,287.  These conditions raise substantial doubt as
to the Company's ability to continue as a going concern. The Company's continued
existence is  dependent  upon its ability to execute its  operating  plan and to
obtain additional debt or equity  financing.  There can be no assurance that the
necessary debt or equity  financing  will be available,  or will be available on
terms  acceptable to the Company.  Management's  operating plan includes working
with Wescor to complete  research,  development and, if warranted,  marketing of
its  hematocrit   technology  and/or  pursuing  other  strategic  alliances  and
licensing  agreements such as the current Agreement with Wescor, Inc. See Item 2
- "Management's Discussion and Analysis."

The accompanying consolidated financial statements of the Company are unaudited.
However,  in management's  opinion,  all adjustments,  consisting only of normal
recurring adjustments necessary for fair presentation of results for the interim
periods shown,  have been made.  Results for interim periods are not necessarily
indicative  of  those  to be  expected  for the full  year.  These  consolidated
financial statements should be read in conjunction with the audited consolidated
financial statements and notes to consolidated  financial statements included in
the Company's annual report on form 10-KSB for the year ended December 31, 2006.


2.       Summary of Significant Accounting Policies

Principles of Consolidation - The consolidated  financial statements include the
accounts of InMedica  and  MicroCor.  All  material  inter-company  accounts and
transactions have been eliminated.

Use of Estimates - The  preparation of financial  statements in conformity  with
accounting  principles  generally  accepted  in the  United  States  of  America
requires  management to make estimates and assumptions  that affect the reported
amounts  of assets and  liabilities  and  disclosure  of  contingent  assets and
liabilities at the date of the financial  statements and the reported amounts of
revenues and expenses during the reporting  period.  Actual results could differ
from those estimates.

                                       7
<PAGE>


ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF
OPERATION

OVERVIEW.  Since 1989, the Company has engaged in research and  development of a
device  to  measure  hematocrit  non-invasively  (the  "Non-Invasive  Hematocrit
Technology"  and/or the "Technology") and fund raising to finance the payment of
research,  development and administrative expenses. Hematocrit is the percentage
of red blood cells in a given volume of human blood.  Research,  development and
administrative  expenses of the Company  relating to the Technology  were funded
during  the  1990's by  borrowing  and by  royalty  revenues  from the sale of a
portable ECG monitor  which  incorporated  Company  technology.  The monitor was
marketed by  Critikon,  Inc.,  then a Johnson and  Johnson  subsidiary.  However
Critikon  discontinued  the  monitor  in 2001 and  InMedica  has not  since  had
revenues from operations. During 2001 the Company and its subsidiary,  MicroCor,
Inc. sold restricted common stock to Chi Lin Technologies,  Ltd. of the Republic
of China  (Taiwan)  for  $1,000,000  and used the funds to  continue  funding of
research,  development  and  administrative  expenses.  Chi Lin  also  signed  a
development agreement under which it performed or financed the Company's primary
research and development  effort conducted  initially in Taiwan and later in the
United  States.  When remaining  funds from the stock sale were expended  during
2003,  the Company began  searching for  additional  funding and/or a partner to
conduct additional research and development. The Company's officers and Chairman
also agreed to the accrual of their wages and consulting fees pending receipt of
funds to pay those obligations. In January 2005, the shareholders of the Company
approved  an  Agreement  with  Wescor  which  provides  additional  funding  for
administrative  expenses  and  provides  for  research  and  development  of the
Hematocrit Technology by Wescor.

PLAN OF OPERATION.  During the 12 months beginning  January,  2007 the Company's
plan of operation is to work  cooperatively  with Wescor in the  development and
possible  demonstration  of the Company's  portable  hematocrit  device to other
companies.   In   connection   with  this  effort,   the  Company  will  require
confidentiality  agreements  from parties to which  disclosure  is made and will
allow such parties to informally  evaluate the  technology in order to determine
their  interest.  During  2007,  Wescor is  expected  to fund the  research  and
development  efforts of MicroCor  pursuant to the Joint  Development  Agreement.
During  2004  and  2005,  the  Company  borrowed  from  Wescor  in order to meet
operating  expenses  and may need to rely on  borrowing  in the  future  to meet
obligations.  While the Company has in the past borrowed from  affiliates,  such
borrowing  may not be  available  in the  future  to meet  obligations  and fund
continued research and development.  If necessary,  InMedica will look for other
funding sources.

                                       8
<PAGE>


LIQUIDITY AND CAPITAL RESOURCES.

The funds  generated  from the sale of stock in 2001 were the sole source of the
Company's  cash  flow  from  May 10,  2001  until  December  31,  2003  and were
sufficient to meet the Company's  operating  expenses through December 31, 2003.
During the years 2004 and 2005 liquidity was generated by borrowings from Wescor
and from the  proceeds of the sale of  MicroCor  stock to Wescor,  Inc.,  a Utah
based medical technology  company that agreed to conduct additional  research on
and  development of the Company's  hematocrit  technology  pursuant to the Joint
Development  Agreement dated September 7, 2004 (the "Agreement").  Liquidity was
also  generated  from sales of restricted  stock to members of  management.  The
Company has funded the expenses of its administrative operations during 2006 and
the first  five  months of 2007 with  funds from a  partially  deferred  minimum
royalty paid to InMedica by MicroCor.  The minimum royalty due InMedica is based
upon terms of the Joint Development Agreement and is $160,000 per year. However,
under the reduced  minimum  royalty  arrangement,  MicroCor  borrowed funds from
Wescor to make one half of the minimum  royalty  payment and InMedica  agreed to
defer the  balance of the  minimum  royalty  payment.  Repayment  of the loan to
Wescor by MicroCor is secured by a 20% security  interest in any future revenues
from the sale of the hematocrit technology by MicroCor, until the loan is repaid
in full. MicroCor is presently  discussing with Wescor an additional loan to pay
one half the minimum  royalty owing to InMedica  during the balance of 2007. The
Company  will also seek  additional  sources of  funding  to pay  administrative
expenses for the balance of the year.

During  September,  2005,  MicroCor issued 500,000 shares of restricted stock to
Wescor pursuant to the Agreement in  consideration of development of a prototype
for the hematocrit technology. Future research and development efforts of Wescor
will continue to be compensated  through additional  issuances of MicroCor stock
to Wescor  pursuant to the  Agreement.  Among other  things,  the  Agreement may
result  in the  disposition  of  InMedica's  ownership  of its  remaining  stock
ownership of MicroCor, Inc., which holds all of the hematocrit patents, business
and  intellectual  property.  However,  if Wescor is  successful  in  completing
development,   the  regulatory  approvals  and  product  introduction  into  the
marketplace, the Company will be entitled to a royalty on sales of the product.

RESULTS OF OPERATIONS.

InMedica  incurred  net losses from  operations  during the three month  periods
ended  March 31,  2007 and 2006.  The  Company  had an  accumulated  deficit  of
$8,684,328 as of March 31, 2007 and no revenues from  operations are expected in
the foreseeable  future. The net loss from operations for the three month period
ended March 31, 2006 decreased  slightly to $31,753  compared to the net loss of
$32,785 for 2006. Expenses should remain constant during 2007.


                                       9
<PAGE>


Item 3:   CONTROLS AND PROCEDURES

The  Company's  Chief  Executive   Officer  and  Chief  Financial  Officer  have
concluded,  based  on  an  evaluation  required  by  paragraph  (b)  of  Section
240.13a-15 or 240.15d-15  of the Rules of the  Securities  Exchange Act of 1934,
conducted as of the end of the period covered by this  Quarterly  Report on Form
10-QSB,  that the Company's  disclosure  controls and  procedures (as defined in
Exchange Act Rules 13a - 15e or 240.15d-15(e)) have functioned effectively.  For
purposes  of this  Item,  the term  DISCLOSURE  CONTROLS  AND  PROCEDURES  means
controls  and other  procedures  of the Company that are designed to ensure that
information required to be disclosed by the Company in the reports that it files
or  submits  under  the  Securities  Exchange  Act (15  U.S.C.  78a ET  SEQ.) is
recorded, processed,  summarized and reported, within the time periods specified
in the Commission's rules and forms. Disclosure controls and procedures include,
without limitation,  controls and procedures designed to ensure that information
required to be  disclosed by the Company in the reports that it files or submits
under  the Act is  accumulated  and  communicated  to the  issuer's  management,
including its principal executive and principal  financial officers,  or persons
performing similar functions, as appropriate to allow timely decisions regarding
required disclosure.

There have been no changes in the  Company's  internal  control  over  financial
reporting identified in connection with the evaluation required by paragraph (d)
of Section 240.13a-15 or 240.15d-15 of the Rules of the Securities  Exchange Act
of 1934,  that occurred  during the Company's last fiscal quarter (the Company's
fourth  fiscal  quarter in the case of an annual  report)  that have  materially
affected,  or is reasonably likely to materially  affect, the Company's internal
control over financial reporting.


                                       10
<PAGE>




     PART II - OTHER INFORMATION

Item 1. Legal Proceedings: None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds: None during
        the period covered by this report.

Item 3. Defaults Upon Senior Securities: None

Item 4. Submission of Matters to a Vote of Security Holders: None

Item 5. Other Information:

         The  disclosure on the facing sheet of this Form 10QSB that the Company
is not a "shell company" as defined in Rule 12b-2 of the Rules of the Securities
Exchange Act of 1934, is based on the Company's conclusion that it has more than
"nominal  operations"  as  described  in Rule 12b-2.  The  Company's  operations
consist of ongoing  operating  expenses reported in its statement of operations,
paid  employees,  a stated  business  purpose of  development  of the hematocrit
technology,  a history of pursuing this purpose, a past history of revenues from
operations and ongoing research and development  conducted by its majority-owned
subsidiary,  MicroCor,  Inc. In the event the Company  were  determined  to be a
"shell  company,"  it  would  be  precluded  from  using  Form  S-8 to  register
securities issued to employees and would be required to make certain disclosures
on Form 8-K  regarding  any  transaction  that  causes it to cease being a shell
company.  Such  disclosures  consist of filings with the Securities and Exchange
Commission of the same type of information that would be required to be filed in
registering  a  class  of  securities  under  the  Exchange  Act.   Examples  of
transactions that could cause a company to cease to be a shell company include a
"reverse  acquisition" or "back door  registration" of a "shell company" with an
operating company. The effect of such disclosure  requirement is to increase the
disclosure  requirements for the  non-reporting or  non-registered  company in a
"reverse acquisition" or "back door registration" as more fully described in SEC
Release  Nos.  33-8587  and  34-52038.  The  Company  has no  present  plans  or
commitments to engage in a "reverse  acquisition,"  "back door  registration" or
similar transaction or to register stock on Form S-8.

Item 6.   Exhibits:

(31.1)   Sarbanes-Oxley Section 302 Certification - Ralph Henson

(31.2)   Sarbanes- Oxley Section 302 Certification- Richard Bruggeman

(32.1)   Sarbanes-Oxley Section 906 Certification

Reports on Form 8-K: None

                                       11
<PAGE>


                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                            INMEDICA DEVELOPMENT CORPORATION


                            /s/ Ralph Henson
                            --------------------------
                            By Ralph Henson, President


                            /s/ Richard Bruggeman
                            --------------------------
                            By Richard Bruggeman, Treasurer


Date:  May 12, 2007
























                                       12

<PAGE>





                EXHIBIT INDEX - INMEDICA DEVELOPMENT CORPORATION
                           FORM 10QSB - MARCH 31, 2007

EXHIBIT NUMBER            DESCRIPTION

         31.1     Section 302 Certifications of Ralph Henson

         31.2     Section 302 Certifications of Richard Bruggeman

         32.2     Sarbanes-Oxley Section 906 Certification







                                       13